Navigation Links
Nuvilex Offers Free Cinnergen Samples in Response to Spike in Consumer Interest
Date:6/5/2009

CHERRY HILL, N.J., June 5 /PRNewswire-FirstCall/ -- Nuvilex, Inc. (OTC Bulletin Board: NVLX), an emerging healthcare consumer products company, announced today that, due to a recent surge of consumer interest, it is offering free Cinnergen samples to people interested in using a whole food supplement to help to prevent conditions associated with pre-diabetes, insulin resistance and fluctuations in blood sugar (glucose) levels.

The surge in interest has been driven by Nuvilex' Internet Marketing Campaign that began April 15, 2009 and to date has produced a 330% increase in site traffic from referring domains such as dLife, Google and Yahoo. Specifically, unique and repeat visits to the Cinnergen site rose from 600 (during March 15-April 15) to 2,000 between April 15 and May 15, 2009.

Cinnergen online sales have also risen to near peak 2008 levels, reaching 500 units in April and May 2009. The free sample offering begins June 8, 2009. A consumer can receive a 16-ounce bottle of Cinnergen for free, but will be responsible for shipping costs. To participate, log onto www.cinnergen.com.

"Cinnergen is an experience product," stated Martin Schmieg, Chairman and CEO of Nuvilex, Inc. "If you try it, we are convinced you will like it and make Cinnergen a part of your daily diet. We are taking aggressive steps to introduce Cinnergen to more people everyday. We have the inventory to invest in this effort and I believe our future sales growth will benefit."

About Cinnergen

Cinnergen is a liquid whole food nutritional supplement that provides vital nutrients to help the body efficiently process sugar, helping to prevent conditions associated with pre-diabetes or diabetes such as insulin resistance and fluctuations in blood sugar (glucose) levels. In addition, Cinnergen may also help the body to more efficiently process fat droplets (lipids) that circulate in blood. One dose (1 fl. Oz.) of Cinnergen delivers amino acids (the building blocks of protein), vitamins, minerals, enzymes, antioxidants, and over a dozen all-natural chemicals derived from plants (including cinnamon bark extract, blueberry leaf extract, ginger root extract, and kelp extract) to the body. Research published in peer-reviewed medical journals suggests that cinnamon bark extract can help to control glucose levels in those who are pre-diabetic or individuals who suffer from type 1 or type 2 diabetes. In addition, studies suggest that two compounds present in blueberry leaf extract --caffeoylquinic acid and caffeic acid --may help to reduce glucose absorption in the small intestine, limit the synthesis of glucose by the liver and kidneys (gluconeogenesis), and speed up the body's metabolism of glucose. Cinnergen contains 0 grams of carbohydrates and fats, has no calories, and does not contain any artificial sweeteners.

About Nuvilex, Inc.

Nuvilex, formerly eFoodSafety.com, is an emerging healthcare consumer products company with a portfolio of aesthetics, dermatology, environmental and nutraceutical products. The company's focus is on developing, licensing and commercializing healthcare products that address the health needs of consumers worldwide. In March 2009, Nuvilex merged with Freedom2 Holdings, Inc., a diversified skin products technology company serving the fast-growing body art, aesthetic, cosmetic and skin therapy markets. More information is available at: http://www.nuvilex.com or www.freedom2inc.com.

Safe Harbor Statement

Statements contained in this presentation that are not strictly historical are "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934. The forward-looking statements are made based on information available as of the date hereof, and the Company assumes no obligation to update such forward-looking statements. Forward-looking statements are sometimes identified by words such as "intends", "anticipates", "believes", "expects", and "hopes" and involve a number of risks and uncertainties that could cause the Company's actual results to differ materially from projected results. All parties are cautioned that such forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially from those in these forward-looking statements. Such risks and uncertainties include but are not limited to demand for the Company's products and services, the planned share exchange with Freedom2 Holdings, Inc., our ability to secure additional financing, and other factors that may be more fully described in reports to shareholders and periodic filings with the Securities and Exchange Commission.

    Investor Relations Contacts:
    Blair Barnes
    Senior Vice President and Chief Financial Officer
    Nuvilex, Inc.
    Ph: 856-433-6088
    Email: bbarnes@nuvilex.com

    Stephanie Carrington/Amy Glynn
    The Ruth Group
    Ph: 646-536-7017/7023
    Email: scarrington@theruthgroup.com
    Email: aglynn@theruthgroup.com

    Press Contact:
    Pat Arcand
    Arcand & Madison Public Relations
    Ph: 617-576-7777
    Email: pat@am-pr.com


'/>"/>
SOURCE Nuvilex, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. eFoodSafety.com, Inc. Changes Name to Nuvilex, Inc., Reflecting New Strategic Direction of Company
2. Nuvilex Infinitink Tattoo Ink Featured on PBS alt.news 26:46 TV Program
3. Nuvilex, Inc. Launches Spring Break Initiatives Designed to Raise Visibility Among Key Demographic Group
4. Nuvilex Provides Conference Call Replay Information
5. Nuvilex, Inc. Announces New Pricing for Cinnergen and Launch of dLife Advertising and Promotion Campaign
6. Nuvilex, Inc.s Marketing Partner, CK41 to Launch purEffect(TM) in May
7. Nuvilex, Inc. Announces Investor Conference Call and Open House
8. Nuvilex Advances Release of Citroxin(TM) Antiviral Surface Cleaner to Help Combat Swine Flu
9. Nuvilex, Inc. Announces Monthly Investor Conference Call
10. Time Magazine Reports on Infinitink Tattoo Ink From Nuvilex
11. Nuvilex Signs Agreement with Jayhur Enterprises to Distribute Infinitink - the Worlds First Permanent, But Easier to Remove Tattoo Ink - in Australia and New Zealand
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... December 07, 2016 , ... ... financial consultation services to residents in the Sacramento/Folsom region, is initiating a charity ... facility. , The Another Choice Another Chance treatment center in Sacramento works to ...
(Date:12/7/2016)... ... December 07, 2016 , ... A. Kevin Spann Insurance, ... families throughout the Five Boroughs, is launching a charity drive to raise funds that ... the traditions and spirit of marines and Navy FMF Corpsmen. Working closely with the ...
(Date:12/7/2016)... ... December 07, 2016 , ... Facial plastic surgeon, Dr. John D. Rachel ... a portion of proceeds to two local organizations: North Chicago Animal Control and Friends ... is a team of authorized and trained volunteers who support rescued animals held ...
(Date:12/7/2016)... ... December 07, 2016 , ... The medical profession is well aware that heart ... major study analyzing heart attacks among 138,602 people recorded a 35% higher number of ... would all agree of course–no time of year is a good time for a ...
(Date:12/7/2016)... Norwalk, CT (PRWEB) , ... December 07, 2016 ... ... the Integrated Infertility and Wellness (IFW) Program at Reproductive Medicine Associates of Connecticut ... which now has a team of three acupuncturists to help patients realize their ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... 7, 2016  Ionis Pharmaceuticals, Inc. (NASDAQ: IONS ), ... a company overview at the BMO Capital Markets Prescriptions for Success ... NY . A live webcast of the presentation ... Ionis website.  The replay will be available within 48 hours and ... ...
(Date:12/7/2016)... (NYSE: LCI ) today announced that the company will ... Conference on December 14, 2016 at 9:20 a.m. (ET) at the ... In addition, the company will host one-on-one meetings with ... Boston Healthcare Conference taking place on December 13, 2016 at the ... , , ...
(Date:12/6/2016)... -- Alopexx Oncology, LLC announced data from a Phase I ... composed of interleukin-2 and a CD20-targeting monoclonal antibody. The ... as Rituxan and maintains the activities of both the ... tumor targeting, engagement of the immune system, and induction ... study (abstract #95954) were presented at the 58 th ...
Breaking Medicine Technology: